Moreover, TNF expression levels are increased in response to EGFR inhibitors, such as erlotinib, through NF-κB activation, which has been observed in EGFR-mutated and unmutated NSCLC cell lines, xenograft models, and archival tissue samples from patients. Here, EGFR is linked to non-small cell lung carcinoma.